This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letter  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Neoplasms  • Diagnosis  • Psoriasis  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Alert me on articles by topic  Social Bookmarking   What's this?

Vito Di Lernia, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Recently, Hernandez et al¹ reported an interesting case of progression of undiagnosed T-cell lymphoma during efalizumab therapy in a 32-year-old man with a 2-year history of a pruritic, erythematous dermatitis that was erroneously diagnosed as psoriasis. The patient developed skin tumors within 3 months of stopping a 4-month cycle of efalizumab therapy, and a diagnosis of tumor-stage erythrodermic mycosis fungoides (MF) was made. A retrospective review of skin biopsy specimens taken before efalizumab therapy had begun confirmed histologic features consistent with pilar MF. The authors conclude that the timing of the tumor-stage progression and initiation of efalizumab treatment in their patient, although not direct evidence of causation, raises suspicion, and they suggest efalizumab avoidance, or at least extreme caution in its use, for patients with a history of lymphoma. In fact, the drug label warns that caution should be used if the drug is being considered . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Progression of Undiagnosed Cutaneous T-Cell Lymphoma During Efalizumab Therapy
Claudia Hernandez, Sophie M. Worobec, Sujata S. Gaitonde, Monika L. Kiripolsky, and Kristen Aquino
Arch Dermatol. 2009;145(1):92-94.
EXTRACT | FULL TEXT  

RELATED LETTER

Efalizumab and Progression of Undiagnosed Follicular Mycosis Fungoides—Reply
Sophie M. Worobec
Arch Dermatol. 2009;145(7):844.
EXTRACT | FULL TEXT